PHARMASEED, MODEL BT-125-1

K992008 · Syncor Pharmaceuticals, Inc. · KXK · Dec 23, 1999 · Radiology

Device Facts

• Record ID: K992008
• Device Name: PHARMASEED, MODEL BT-125-1
• Applicant: Syncor Pharmaceuticals, Inc.
• Product Code: KXK · Radiology
• Decision Date: Dec 23, 1999
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 892.5730
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The intended use of Syncor Pharmaceuticals' BT-125-1 seeds is to deliver radiation for brachytherapy in the treatment of cancer with sources in close proximity to, or within, the tumor.

Device Story

PharmaSeed BT-125-1 Brachytherapy Seeds are radioactive sources designed for interstitial or intracavitary cancer treatment. Seeds are implanted directly into or near tumor sites by clinicians to deliver localized radiation therapy. Device functions as a permanent or temporary implant to provide targeted dose distribution to malignant tissue. Benefit includes localized tumor control while minimizing radiation exposure to surrounding healthy tissue.

Clinical Evidence

No clinical data provided; substantial equivalence based on technological characteristics and intended use.

Technological Characteristics

Radioactive brachytherapy seeds; intended for interstitial/intracavitary implantation. Class II device (21 CFR 892.5730).

Indications for Use

Indicated for brachytherapy treatment of cancer by delivering radiation to tumors via sources placed in close proximity to or within the tumor tissue.

Regulatory Classification

Identification

A radionuclide brachytherapy source is a device that consists of a radionuclide which may be enclosed in a sealed container made of gold, titanium, stainless steel, or platinum and intended for medical purposes to be placed onto a body surface or into a body cavity or tissue as a source of nuclear radiation for therapy.

Special Controls

*Classification.* Class II (special controls). A prostate seeding kit intended for use with a radionuclide brachytherapy source only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.

Submission Summary (Full Text)

{0}------------------------------------------------

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Image /page/0/Picture/3 description: The image shows a black and white logo. The logo is a symbol of the Department of Health and Human Services. The symbol is a stylized representation of a human figure, with three overlapping profiles facing to the right. The profiles are connected at the top and bottom, creating a sense of unity and collaboration.

DEC 2 3 1999

Gary Gilmore President and General Manager Syncor Pharmaceuticals, Inc. 1313 Washington Avenue Golden, Colorado 80401

RE:

K992008 PharmaSeed BT-125-1 Brachytherapy Seeds Dated: September 24, 1999 Received: September 30, 1999 Regulatory Class: II 21 CFR 892.5730/Procode: 90 KXK

Dear Mr. Gilmore:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP requiration may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Marufacturers Assistance at its toll-free number [phone] or [phone], or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

CAPT Daniel G. Schultz, M.D. Acting Director, Division of Reproductive. Abdominal, Ear, Nose and Throat, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{1}------------------------------------------------

510(k) Number (if known):

K 992008

Device Name:

PharmaSeed BT-125-1 Brachytherapy Seeds

## Indications for Use:

The intended use of Syncor Pharmaceuticals' BT-125-1 seeds is to deliver radiation for brachytherapy in the treatment of cancer with sources in close proximity to, or within, the tumor.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

| Prescription Use<br>(Per 21 CFR 801.109) | |
|------------------------------------------|--|
|------------------------------------------|--|

OR

| Over-The-Counter Use | (Optional Format 1-2-96) |
|----------------------|--------------------------|
|----------------------|--------------------------|

(Division Sign-Off)

Division of Reproductive, Abdominal, ENT, and Radiological Devices

| 510(k) Number | K992008 |
|---------------|---------|
|---------------|---------|

Concurrence of CDRH; Office of Device Evaluation (ODE)